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Abstract
Background: The purpose of this study was to assess the impact on dose to the planning target volume (PTV) and
organs at risk (OAR) by using four differently generated CT datasets for dose calculation in stereotactic body radiotherapy
(SBRT) of lung and liver tumors. Additionally, dose differences between 3D conformal radiotherapy and volumetric
modulated arc therapy (VMAT) plans calculated on these CT datasets were determined.
Methods: Twenty SBRT patients, ten lung cases and ten liver cases, were retrospectively selected for this study. Treatment
plans were optimized on average intensity projection (AIP) CTs using 3D conformal radiotherapy (3D-CRT) and volumetric
modulated arc therapy (VMAT). Afterwards, the plans were copied to the planning CTs (PCT), maximum intensity
projection (MIP) and mid-ventilation (MidV) CT datasets and dose was recalculated keeping all beam parameters and
monitor units unchanged. Ipsilateral lung and liver volumes and dosimetric parameters for PTV (Dmean, D2, D98, D95),
ipsilateral lung and liver (Dmean, V30, V20, V10) were determined and statistically analysed using Wilcoxon test.
Results: Significant but small mean differences were found for PTV dose between the CTs (lung SBRT: ≤2.5 %;
liver SBRT: ≤1.6 %). MIPs achieved the smallest lung and the largest liver volumes. OAR mean doses in MIP
plans were distinctly smaller than in the other CT datasets. Furthermore, overlapping of tumors with the
diaphragm results in underestimated ipsilateral lung dose in MIP plans. Best agreement was found between
AIP and MidV (lung SBRT). Overall, differences in liver SBRT were smaller than in lung SBRT and VMAT plans
achieved slightly smaller differences than 3D-CRT plans.
Conclusions: Only small differences were found for PTV parameters between the four CT datasets. Larger
differences occurred for the doses to organs at risk (ipsilateral lung, liver) especially for MIP plans. No relevant
differences were observed between 3D-CRT or VMAT plans. MIP CTs are not appropriate for OAR dose
assessment. PCT, AIP and MidV resulted in similar doses. If a 4DCT is acquired PCT can be omitted using AIP
or MidV for treatment planning.
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Introduction
Stereotactic body radiotherapy (SBRT) is well established in
the treatment of tumors and metastases of lung and liver
[1–4]. Typically, patients are treated in a few sessions using
high doses per fraction. To minimize dose to organs at risk
(OAR), small safety margins for the PTV are applied, which
demands high precision in localization of the tumor, patient
positioning and delivery of radiotherapy. A slow 3D com-
puter tomography (CT) scan during free respiration can be
acquired as planning CT (PCT) for treatment plan-
ning [5, 6]. Movement of the tumor can be assessed
by four-dimensional computer tomography (4DCT).
Using this motion information different approaches
have been proposed to generate the planning target
volume (PTV). For the internal target volume (ITV)
concept the outline of the tumor is merged over all
breathing phases of the 4DCT and a margin is added
to generate the PTV [7, 8]. Maximum intensity pro-
jection (MIP) or average intensity projection (AIP)
CT datasets can be calculated from the 4DCT to de-
lineate the tumor herein [9–11]. Another group
suggested the generation of a mid-ventilation CT
dataset (MidV) for target definition and treatment
planning [12].
Mostly SBRT planning is performed on one of the previ-
ously mentioned CT datasets. Novel approaches use 4D
planning on 4DCT datasets [13]. Deformable image regis-
tration tools are applied to map the dose on PCT or end
exhalation phase [14, 15]. But 4D planning is time consum-
ing and tools for deformable image registration are not
widely spread. The dosimetric differences between 4D and
3D treatment planning seem to be small and may not be
clinically relevant [16]. Therefore 3D planning on a single
CT dataset is still common practice.
Up to now only a limited number of studies compared
the differences between CT datasets for treatment plan-
ning [17, 18]. These studies reported only comparisons
between CT datasets for lung SBRT using 3D conformal
radiotherapy (3D-CRT).
Volumetric modulated arc therapy (VMAT) [19] is
nowadays widely used and increasingly for SBRT due to
its improved treatment efficiency [20–22].
The aim of this study was to compare the dosimetric im-
pact of using four different CT datasets (PCT, MIP, AIP
and MidV) for SBRT dose calculation. We compared the
dosimetric impact for lung and liver SBRT concerning the
dose to PTV and OARs (ipsilateral lung and liver). Add-
itionally, the influence of two different planning techniques
(3D-CRTand VMAT) on calculated dose was investigated.
Material and methods
Patients and CT datasets
Twenty SBRT patients from our clinic, ten lung cases
and ten liver cases, were retrospectively selected for
this study. Each patient received a slow 3D-CT for
treatment planning (PCT). Additionally, a 4DCT scan
was acquired to receive motion information for delin-
eation of the planning target volume. Data acquisition
was performed using a 16 Multi-slice Somatom Emo-
tion scanner (Siemens medical solutions, Erlangen,
Germany). Patient’s breathing curve was measured
with the Real-Time Position Management system
(Varian Medical Systems, Palo Alto, CA, USA) during
4DCT scanning. Afterwards, the breathing curves
were transfered to the syngo software (Siemens med-
ical solutions, Erlangen, Germany) which sorted the
acquired data retrospectively due to the temporal cor-
relation with the breathing curve. The data were
sorted into 10 phase-bins resulting in 3D-datasets
which depict the imaged volume as 10 phases over
the respiratory cycle.
From the 10 phases of the 4DCT an average intensity
projection (AIP) CT was calculated representing the
mean intensity of each voxel over all phases. A max-
imum intensity projection (MIP) CT dataset was also
calculated which shows the maximum intensity of each
voxel over all phases. AIP and MIP CT datasets were
calculated using self-written programs in Matlab (Math-
Works, Natick, MA, USA).
According to the concept of mid-ventilation CT scan
[12] the tumor motion was determined by delineating
the tumor in all phases of the 4DCT and evaluating the
center of mass coordinates. The time-weighted mean
tumor position was determined and the phase of the 10
phases was selected as mid-ventilation CT (MidV) which
was closest to this mean tumor position. Due to the low
contrast between tumor and liver tissue it was not pos-
sible to delineate the tumor in all 4DCT phases for liver
SBRT. Therefore the position of the diaphragm was de-
termined for all phases and the phase of the 4DCT scan
with the diaphragm position closest to the mean position
was selected as MidV CT. It is well known that the
whole liver does not move in a linear fashion [23].
Therefore this approach is only an estimation of the real
mean tumor position.
The image resolution of the CT datasets created from
the 4DCT (AIP, MIP, MidV) was 1.0x1.0x2.1 mm3. The
PCT datasets had a resolution of 1.0x1.0x3.0 mm3.
Contouring and treatment planning
Contouring and treatment planning was performed with
the Eclipse 10 planning system (Varian Medical Systems,
Palo Alto, CA, USA). The ITV concept was used in this
study as it is the applied concept for SBRT treatments in
our clinic. Gross tumor volumes (GTVs) were contoured
in all phases of the 4DCT and an ITV was generated.
PTVs were created by adding an uniform margin of 5 mm
to the ITV. The mean volume of the PTVs over all
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patients for lung SBRT was 115.2 cm3 (range: 27.1 cm3 to
218.8 cm3) and 153.5 cm3 for liver SBRT (range: 44.4 cm3
to 202.3 cm3). Afterwards, the PTVs were copied to the
four CT datasets. For lung SBRT, the total ipsilateral lung
volume was contoured as OAR on all four CT datasets
and the total liver volume for the liver SBRT cases.
Two treatment plans were optimized on the AIP
CT dataset for each patient using 3D-CRT (7–9 co-
planar fields) and VMAT (2–3 partial arcs) technique.
The prescription dose was 7 Gy delivered in 5 frac-
tions corresponding to the 60 % isodose level sur-
rounding the PTV. 3D-CRT plans were normalized to
a dose of 100 % at the beam isocenter. For VMAT
plans the dose was normalized that the 60 % isodose
covers 100 % of the PTV. All optimized plans had a
dose maximum between 101 and 105 % in the center
of the PTV. Dose calculation was performed using
the AAA algorithm (version 10.0.28) and heterogen-
eity correction. All plans were calculated for treat-
ment on a Clinac Trilogy linear accelerator equipped
with a 120 HD MLC (Varian Medical Systems, Palo
Alto, CA, USA). Each leaf bank has 60 leafs: the
inner 30 have a leaf width of 2.5 mm; the outer 30
have a leaf width of 5.0 mm. A photon energy of 15
MV was used for all plans. The optimized plans were
copied to the PCT, MIP and MidV CT datasets and
dose was recalculated keeping all beam parameters
and monitor units unchanged. This enables the evalu-
ation of dosimetric differences between the four CT
datasets which arise from different density values.
Data evaluation
Dosimetric parameters for PTV (Dmean, D2, D98, D95)
and the ipsilateral lung and liver (Dmean, V30, V20,
V10) were determined on all CT datasets. Further, we
assessed the absolute volume of the lung and the liver
(Vlung, Vliver). All parameters were compared and sta-
tistically analyzed using Wilcoxon test. A p-value <0.05
was considered as statistically significant. The statistical
analyses were performed using SPSS Software for
Windows version 23.0 (SPSS Inc., Chicago, IL, USA).
Results
Dose to PTV
In Fig. 1 axial slices of the four CT datasets with dose
distributions for a lung and a liver SBRT patient are
Fig. 1 Axial and coronal slices with dose distributions for a lung and a liver SBRT patient. The size of lung and liver appears differently in the CT
datasets. PCT: planning CT, AIP: average intensity projection CT, MIP: maximum intensity projection CT, MidV: mid-ventilation CT
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depicted. Relative differences of doses over all patients
for the PTV are depicted in Table 1 (lung SBRT) and
Table 2 (liver SBRT).
For the lung SBRT the largest mean difference was
found for 3D-CRT plans and parameter D95 (MIP vs.
PCT: 2.5 ± 1.8 %). The differences between CT datasets
were ≤2.5 % (3D-CRT) or ≤2.2 % (VMAT). Nevertheless,
many values showed significant differences (p < 0.05,
Table 1). AIP and MidV achieved the best agreements
over all parameters. Over all patients, the mean differ-
ence for all parameters was somewhat higher in MIP
CTs compared to the others.
The liver SBRT plans showed smaller dose differences
for the PTV between the CT datasets than the lung
SBRT plans (Table 2). The largest differences were found
for 3D-CRT plans and D95 (MIP vs. MidV: −1.6 ± 1.3 %).
All other differences between CT datasets were ≤1.2 %.
AIP and MidV CT resulted in the best agreements over
all parameters. In comparison to 3D-CRT plans VMAT
showed slightly smaller differences over all parameters.
Organ volume
Figure 2 shows the lung and liver volumes of all patients.
In MIP CTs the lung volume was significantly smaller
than in all other CT datasets (p ≤ 0.01). The largest vol-
umes were contoured in PCTs but that was not statisti-
cally significant. The best agreement for lung volumes
was found between MidV and AIP CTs (−1.5 ± 3.0 %).
For the liver SBRT cases, the largest liver volume was al-
ways contoured in MIP CTs (p ≤ 0.01). The smallest dif-
ferences were found between PCT and AIP (0.5 ± 4.8 %).
PCT and AIP achieved also the smallest liver volumes as
compared to the other CT datasets.
Table 1 PTV dose differences in lung SBRT between the CT
datasets
3D-CRT VMAT
CT datasets Δ [%] P value Δ [%] P value
ΔDmean PCT vs AIP −0.8 ± 0.5 0.01
* −0.5 ± 0.5 0.01*
MIP vs AIP 1.5 ± 1.4 0.01* 1.6 ± 1.5 0.01*
MidV vs AIP 0.0 ± 0.3 0.96 −0.1 ± 0.3 0.72
MIP vs PCT 2.4 ± 0.7 0.01* 2.2 ± 1.5 0.01*
MidV vs PCT 0.8 ± 0.7 0.02* 0.5 ± 0.6 0.06
MIP vs MidV 1.6 ± 1.3 0.01* 1.7 ± 1.5 0.01*
ΔD2 PCT vs AIP −0.5 ± 0.7 0.04
* −0.2 ± 0.8 0.29
MIP vs AIP 1.0 ± 1.5 0.07 1.6 ± 2.0 0.01*
MidV vs AIP −0.1 ± 0.4 0.39 0.0 ± 0.5 0.96
MIP vs PCT 1.5 ± 2.0 0.01* 1.9 ± 1.9 0.01*
MidV vs PCT 0.4 ± 0.9 0.13 0.2 ± 1.1 0.33
MIP vs MidV 1.1 ± 1.6 0.06 1.7 ± 2.0 0.01*
ΔD98 PCT vs AIP −1.4 ± 0.4 0.01
* −1.1 ± 0.7 0.01*
MIP vs AIP 1.0 ± 1.6 0.07 1.0 ± 1.4 0.02*
MidV vs AIP 0.2 ± 0.4 0.09 0.0 ± 0.4 0.59
MIP vs PCT 2.4 ± 1.9 0.01* 2.2 ± 1.7 0.01*
MidV vs PCT 1.7 ± 0.6 0.01* 1.1 ± 0.7 0.01*
MIP vs MidV 0.7 ± 1.5 0.20 1.0 ± 1.4 0.07
ΔD95 PCT vs AIP −1.3 ± 0.3 0.01
* −0.9 ± 0.4 0.01*
MIP vs AIP 1.2 ± 1.6 0.02* 1.0 ± 1.4 0.03*
MidV vs AIP 0.2 ± 0.4 0.09 0.0 ± 0.4 0.68
MIP vs PCT 2.5 ± 1.8 0.01* 1.9 ± 1.6 0.01*
MidV vs PCT 1.5 ± 0.5 0.01* 0.9 ± 0.4 0.01*
MIP vs MidV 1.0 ± 1.4 0.04* 1.0 ± 1.5 0.06
Relative differences over all patients (mean ± standard deviation) of dosimetric
values for PTV in lung SBRT between the different CT datasets for 3D-CRT and
VMAT plans. PCT planning CT, AIP average intensity projection CT, MIP maximum
intensity projection CT, MidV mid-ventilation CT. *assigns statistical significant
values (p < 0.05)
Table 2 PTV dose differences in liver SBRT between the CT
datasets
3D-CRT VMAT
CT datasets Δ [%] P value Δ [%] P value
ΔDmean PCT vs AIP −0.5 ± 0.7 0.04
* −0.4 ± 0.5 0.03*
MIP vs AIP −1.1 ± 0.7 0.01* −0.9 ± 0.7 0.01*
MidV vs AIP 0.0 ± 0.3 0.39 0.1 ± 0.4 0.24
MIP vs PCT −0.7 ± 0.9 0.06 −0.5 ± 0.7 0.07
MidV vs PCT 0.4 ± 0.8 0.06 0.5 ± 0.6 0.05
MIP vs MidV −1.1 ± 0.7 0.01* −0.9 ± 0.5 0.01*
ΔD2 PCT vs AIP −0.3 ± 0.4 0.05 −0.3 ± 0.5 0.06
MIP vs AIP −1.2 ± 0.7 0.01* −1.1 ± 0.6 0.01*
MidV vs AIP −0.2 ± 0.4 0.14 −0.1 ± 0.4 0.67
MIP vs PCT −0.8 ± 0.8 0.01* −0.7 ± 0.7 0.01*
MidV vs PCT 0.1 ± 0.7 0.48 0.2 ± 0.7 0.33
MIP vs MidV −0.9 ± 0.6 0.01* −0.9 ± 0.5 0.01*
ΔD98 PCT vs AIP −0.8 ± 0.9 0.02
* −0.5 ± 0.4 0.01*
MIP vs AIP −0.6 ± 1.3 0.06 −0.8 ± 0.6 0.01*
MidV vs AIP 0.4 ± 0.5 0.03* 0.1 ± 0.3 0.15
MIP vs PCT 0.2 ± 0.9 0.92 −0.4 ± 0.7 0.10
MidV vs PCT 1.2 ± 1.0 0.01* 0.6 ± 0.5 0.02*
MIP vs MidV −1.0 ± 1.2 0.01* −0.9 ± 0.6 0.01*
ΔD95 PCT vs AIP −0.7 ± 0.8 0.02
* −0.5 ± 0.4 0.02*
MIP vs AIP −1.2 ± 1.7 0.07 −0.8 ± 0.6 0.01*
MidV vs AIP 0.4 ± 0.6 0.04* 0.1 ± 0.3 0.08
MIP vs PCT −0.5 ± 1.9 0.72 −0.4 ± 0.7 0.14
MidV vs PCT 1.1 ± 0.9 0.01* 0.6 ± 0.6 0.02*
MIP vs MidV −1.6 ± 1.3 0.01* −0.9 ± 0.5 0.01*
Relative differences over all patients (mean ± standard deviation) of dosimetric
values for PTV in liver SBRT between the different CT datasets for 3D-CRT and
VMAT plans. PCT planning CT, AIP average intensity projection CT, MIP maximum
intensity projection CT, MidV mid-ventilation CT. *assigns statistical significant
values (p < 0.05)
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Dose to organs at risk
Relative differences for the ipsilateral lung dose over all
patients are listed in Table 3. For the difference of abso-
lute lung volumes receiving a certain dose (Vx), best
agreement was found between AIP and MidV with mean
differences ≤1.2 %. PCT achieved up to 8.9 % differences
(VMAT) to AIP and MidV with smaller differences with
decreasing dose. In MIP plans the absolute volumes re-
ceiving certain doses are significantly smaller than in all
other CT datasets. Only small differences (≤2.4 %) were
found for lung parameters between 3D-CRT and VMAT
plans. No significant differences were found for lung
Dmean between AIP, PCT and MidV. MIP plans resulted
in distinctly lower lung Dmean. As the results were unex-
pected (smaller lung volumes in MIP resulting in smaller
lung Dmean in MIP), we analyzed the CTs by tumor loca-
tion. In 4 out of 10 patients the PTV partially overlaps
with the diaphragm. If these patients were excluded
from the analysis (Fig. 3) lung Dmean in MIP plans
was higher than in plans on the other CT datasets
(3.3–4.0 %). The difference in lung volume receiving
a certain dose (Vx) between MIP and the other CT
datasets decreased distinctly.
In liver SBRT (Table 4), MIP plans achieved smaller liver
Dmean values than plans calculated on the other CT
datasets. The difference for V30, V20 and V10 was always
≤2.5 % between AIP, MidV and PCT. MIP plans resulted in
somewhat larger differences for Vx (≤5.4 %). 3D-CRT and
VMAT plans achieved nearly the same results for all CT
datasets and OAR dose parameters (Δ ≤1.0 %).
Discussion
For stereotactic treatment of lung and liver tumors several
CT datasets are acquired (PCT, 4DCT) or can be generated
(MIP, AIP, MidV) for treatment planning. In this study the
impact of four different CT datasets for treatment planning
on dose to PTV and OARs was evaluated for lung and liver
SBRTcases using 3D-CRT or VMAT.
PTV doses in lung SBRT showed only small but par-
tially statistically significant differences between the
treatment plans on different CT datasets regardless of
the chosen technique (3D-CRT or VMAT), with the lar-
gest mean difference of 2.5 % (D95). Similar data are
available in literature for 3D-CRT SBRT. Tian et al. [18]
compared dosimetric differences in lung SBRT between
3D-CRT plans calculated on AIP, MIP and PCT datasets.
They reported small but significant dose differences for
PTV between the CT datasets. They mentioned that
these small differences may not reflect clinical significant
changes.
Fig. 2 Lung and a liver volumes of all patients. In MIP CTs the determined lung volume was always smaller and the liver volume was always
larger than in the other CT datasets. AIP: average intensity projection CT, PCT: planning CT, MIP: maximum intensity projection CT, MidV:
mid-ventilation CT
Oechsner et al. Radiation Oncology  (2015) 10:249 Page 5 of 9
For the liver SBRT cases dose differences for PTV be-
tween the CT datasets were even smaller (≤1.6 %) than
for lung SBRT. This might be due to the negligible dens-
ity differences between soft tissues in the abdomen,
which are furthermore also significantly smaller than in
the thorax. Therefore different tissue representations in
the CT datasets have less effect on calculated PTV doses
in liver SBRT.
Nonetheless, if any of these four CT datasets is se-
lected for treatment planning, a treatment plan will be
calculated which fulfills the dose constraints for PTV
dose coverage on either of the CT datasets. But, the CT
dataset has a major impact on the contoured lung and
liver volume and hence on dosimetric parameters for
OARs. Therefore OAR dose as depicted by the CT data-
sets might be a major issue. MIP CTs always achieved
the smallest lung volume and the largest liver volume.
This is a consequence of the image generation of MIP
by using the highest voxel intensities of the 4DCT
phases. Differences between the other CT datasets for
lung volumes were also found but these were small and
not statistically significant. For the liver cases MidV CT
achieved significantly larger liver volumes than PCT and
AIP.
Concerning the lung volume receiving a certain dose
(Vx), MIP plans achieved distinctly smaller values than
all other plans. Except for V30 (PCT), the other CT data-
sets showed no significant differences in Vx.
In this work and also in Ref [18] Vx values were deter-
mined as absolute organ volumes receiving a certain
dose. In clinical practise Vx is often referred to relative
organ volumes. This would result in smaller differences
between Vx of MIP and the other CT datasets because
of the smaller lung volumes in MIP images.
Another important clinical dose parameter for the
lung is Dmean, which was not reported in Ref [18]. Like-
wise, Dmean showed no significant differences between
AIP, PCT and MidV, but larger differences for MIP (−5.6
to−6.5 %) over all patients. Han et al. [17] compared
dose to the lung (lung-ITV) between PCT and AIP. They
did not find significant differences in OAR dose (Dmean
and Dmax) between PCT and AIP datasets. This is in ac-
cordance to our findings for PCT and AIP.
Furthermore, the impact of tumor location on dose
differences between the CT datasets was analysed in our
study. In MIP plans the tumor location can have a large
impact on lung dose (Fig. 3). Over all patients lung
Dmean in MIP plans was about 6 % smaller than in the
other plans. If the four lung cases in which the tumor
overlaps with the diaphragm were excluded from the
analysis, MIP plans achieved on average higher lung
Dmean values than plans of the other datasets. Differ-
ences for Vx are also distinctly reduced. This could be
seen in 3D-CRT as well as in VMAT plans. This effect
wasn’t found for AIP, PCT and MidV CT datasets. For
the liver SBRT cases no such effect of tumor location
could be seen in our data. This effect is obviously due to
the image generation of MIP. Lung near the diaphragm
is replaced by liver which results in lower lung dose.
However, the number of patients in this study is too
small for a detailed analysis of the influence of tumor lo-
cation on dose differences between the CT datasets.
Distinctly less publication are available on liver SBRT.
To our knowledge no study compared the influence of
different CT datasets on dose in liver SBRT. Over all pa-
tients MIP plans resulted in the smallest mean liver
dose. This is due to the largest contoured liver volume
in MIP CTs. Otherwise MIP achieved larger Vx values
than the other CT datasets, because of Vx are related to
absolute OAR volumes in this work.
Compared to the lung, the liver Dmean between MidV
and AIP or PCT showed larger differences (−2.3 to
Table 3 Differences for ipsilateral lung dose in lung SBRT
3D-CRT VMAT
CT datasets Δ [%] P value Δ [%] P value
ΔDmean PCT vs AIP 0.6 ± 6.6 0.39 1.2 ± 6.8 0.29
MIP vs AIP −5.6 ± 14.5 0.21 −5.6 ± 13.7 0.20
MidV vs AIP 0.4 ± 2.8 0.80 0.4 ± 2.7 0.80
MIP vs PCT −6.0 ± 14.9 0.13 −6.5 ± 14.1 0.06
MidV vs PCT 0.2 ± 7.7 0.39 −0.4 ± 7.7 0.24
MIP vs MidV −5.9 ± 14.7 0.28 −5.8 ± 13.9 0.14
ΔV30 PCT vs AIP 7.2 ± 12.7 0.07 8.9 ± 13.5 0.07
MIP vs AIP −23.6 ± 17.0 0.01* −25.0 ± 16.5 0.01*
MidV vs AIP −0.6 ± 2.3 0.39 −0.6 ± 2.5 0.33
MIP vs PCT −28.0 ± 18.5 0.01* −30.4 ± 17.7 0.01*
MidV vs PCT −6.1 ± 11.2 0.07 −7.4 ± 11.6 0.06
MIP vs MidV −23.1 ± 16.9 0.01* −24.5 ± 16.5 0.01*
ΔV20 PCT vs AIP 3.5 ± 10.2 0.07 4.9 ± 10.6 0.07
MIP vs AIP −22.2 ± 15.4 0.01* −22.4 ± 14.1 0.01*
MidV vs AIP −0.9 ± 3.4 0.17 −0.9 ± 3.4 0.17
MIP vs PCT −24.4 ± 16.1 0.01* −25.5 ± 15.2 0.01*
MidV vs PCT −3.3 ± 10.7 0.07 −4.6 ± 10.6 0.07
MIP vs MidV −21.4 ± 15.4 0.01* −21.6 ± 14.1 0.01*
ΔV10 PCT vs AIP 1.6 ± 9.1 0.24 1.9 ± 9.8 0.29
MIP vs AIP −20.8 ± 11.7 0.01* −21.8 ± 12.7 0.01*
MidV vs AIP −1.2 ± 4.3 0.17 −1.2 ± 4.5 0.20
MIP vs PCT −21.8 ± 11.1 0.01* −23.0 ± 11.9 0.01*
MidV vs PCT −2.0 ± 10.2 0.11 −2.2 ± 10.9 0.14
MIP vs MidV −19.7 ± 12.1 0.01* −20.7 ± 12.8 0.01*
Relative differences for ipsilateral lung dose (mean ± standard deviation) in
lung SBRT between the different CT datasets for 3D-CRT and VMAT plans. PCT
planning CT, AIP average intensity projection CT, MIP maximum intensity
projection CT, MidV mid-ventilation CT. *assigns statistical significant
values (p < 0.05)
Oechsner et al. Radiation Oncology  (2015) 10:249 Page 6 of 9
−3.1 %). This is due to the significant larger liver volume
contoured in MidV CTs. Statistically significant differ-
ences for liver volumes receiving a certain dose in MidV
CTs were only found for V10.
VMAT is nowadays widely used and increasingly for
SBRT. Several studies reported application of VMAT for
lung and/or liver SBRT [21, 22, 24, 25] noting good dose
coverage, sparing of OARs and reduced dose delivery
times. The influence of different CT datasets for dose
calculation between 3D-CRT and VMAT plans showed
only small differences for PTV dose parameters between
both techniques (≤0.6 % in lung SBRT, ≤0.7 % in liver
SBRT). Differences in OAR doses were also small
(<2.4 %). Overall VMAT showed somewhat smaller dose
differences compared to 3D-CRT. This could be due to
the fact, that in VMAT the beam paths through the body
are spread over a larger area and local differences in tis-
sue densities between the CT datasets have less effect on
dose distribution.
When 4DCT was introduced into the routine treat-
ment planning and became widely available, the question
that came up was whether we could trust the planning
performed on the CT datasets reconstructed from the
4DCT. The simplest way to assess the differences in
these CTs was to copy the plans and recalculate the
dose. If 4DCT is available, the AIP is one of the options
for treatment planning. All plans in this study were
planned on the AIP CT and then copied to the other CT
datasets. We intended to evaluate dose differences which
arise only from density differences between the CT data-
sets. Due to the similar PTV dose coverage in all four
CT datasets we expect that only very small changes are
necessary to adapt the plans to PCT, MIP or MidV CTs.
As already mentioned in the discussion the major issue
is the dose to OARs. These are always depicted differ-
ently in the CT datasets resulting in different contoured
volumes and thus in different calculated doses.
One limitation of our study was the dose calculation
with an AAA algorithm. More sophisticated algorithms
like Monte Carlo based methods or the Acuros XB from
Varian [26, 27] achieve higher accuracy especially in
areas with high gradients in electron density (i.e. lung).
AAA tends to overestimate the dose in these regions. If
lung SBRT plans are calculated with AAA and Acuros,
the D98 [28] can differ up to +12.3 % for AAA whereas
Dmean shows only small differences [28, 29]. However a
recalculation with Acuros is expected to have only a
small impact on the dose for liver SBRT.
Which CT dataset might be most suitable for treat-
ment planning in lung or liver SBRT? Overall, differ-
ences in PTV dose parameters were small between
the four CT datasets. The delineation of OAR vol-
umes in the MIP dataset resulted in large differences
with underestimation (lung) or overestimation (liver)
of volumes due to the image generation properties.
This again has an influence on the calculated OAR
Fig. 3 Analysis of lung dose by tumor location. Bars show the mean difference (±standard deviation) in lung Dmean and Vx over all patients
between MIP and the other CT datasets. Mean values over all 10 patients resulted in large differences. If patients with tumor overlap to the
diaphragm were excluded (6 patients left), the differences decreased drastically. AIP: average intensity projection CT, PCT: planning CT, MIP:
maximum intensity projection CT, MidV: mid-ventilation CT
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mean dose and Vx which differ significantly compared
to the other CT datasets. Therefore, MIP is not suit-
able for treatment planning of lung and liver SBRT.
Several work compared PTV volume definition by
using different CT datasets [9–11]. Depending on the
clinical practise in the department it might be helpful
to have more than one CT dataset at hand for the
whole therapy planning process.
The PCT achieved good agreement to AIP and
MidV CT for PTV coverage. OAR volumes in the
PCT are in accordance to AIP volumes (lung and
liver) and MidV volumes (lung). Significant differences
between PCT and MidV were found in mean dose to
the liver. As already mentioned in Ref. [17, 18] image
quality in free breathing PCT is often reduced due to
motion. Furthermore, if a 4DCT scan is acquired
anyway to receive motion information of the tumor,
the acquisition of an additional PCT seems to be
unnecessary. This would spare the patient from
additional CT dose. Under such circumstances a PCT
scan is not preferable to AIP or MidV.
The MidV plans achieved good agreement to AIP
for PTV doses, lung volumes and lung doses. Signifi-
cant differences were found for liver volume and liver
V10. The MidV CT as used in this work requires de-
termination of the time weighted mean tumor pos-
ition in the 4DCT by contouring the GTVs in every
phase. The mid-ventilation approach [12] uses the
exact phase of the 4DCT which is closest to the
mean tumor position. In our work we selected the
one of 10 evenly distributed phases as mid-ventilation
CT (MidV) with the tumor position closest to the
time weighted mean tumor position. This is only a
rough estimate but we would expect only negligible
effects for dose calculation. A refinement of the MidV
concept is the reconstruction of a mid-position CT
(MidP) [30]. This concept was recently applied for
liver SBRT [31]. The MidP requires deformable image
registration methods and is beyond the scope of our
work.
The AIP-CT achieved good agreement for PTV dose
to MidV and PCT plans. For the lung cases AIP and
MidV achieved nearly the same results. The AIP
reconstruction from the 4DCT dataset is straight
forward and available on a variety of commercial soft-
ware. Assuming a good image quality of the 4DCT,
using AIP for treatment planning needs less effort
and creates reliable results for dose calculation of
PTV and OARs.
For clinical routine one other issue to be taken into
consideration is the daily setup correction by image
guidance. In clinical practice the CT dataset used for
treatment planning is usually the CT dataset used also
for alignment with the linac on board imaging - e.g.
cone beam CTs (CBCT). As reported in Ref. [32], using
AIP or MIP CT datasets for alignment to CBCTs can
result in different shifts especially for large moving
tumors or asymmetrical breathing patterns.
Conclusions
The dosimetric impact of using four different CT
datasets for dose calculation showed only small differ-
ences for the dose to the PTV. No differences were
observed between 3D-CRT or VMAT plans with re-
spect to the chosen CT dataset. Larger differences
were found for the dose to the organs at risk (ipsilat-
eral lung, liver) especially for MIP plans. MIP plans
seem not to be reliable for OAR dose assessment and
should not be used for treatment planning. PCT, AIP
and MidV resulted in similar doses and are all applic-
able. Assuming a 4DCT is acquired in any case, an
additional PCT can be omitted using AIP or MidV
for treatment planning.
Table 4 Differences for liver dose in liver SBRT
3D-CRT VMAT
CT datasets Δ [%] P value Δ [%] P value
ΔDmean PCT vs AIP 0.9 ± 3.8 0.88 0.9 ± 3.9 0.76
MIP vs AIP −5.8 ± 4.7 0.04* −5.3 ± 4.6 0.05
MidV vs AIP −2.3 ± 3.4 0.07 −2.1 ± 3.3 0.08
MIP vs PCT −6.6 ± 3.0 0.01* −6.2 ± 2.9 0.01*
MidV vs PCT −3.1 ± 3.2 0.03* −3.0 ± 3.3 0.04*
MIP vs MidV −3.6 ± 2.7 0.01* −3.2 ± 2.7 0.01*
ΔV30 PCT vs AIP 1.7 ± 4.9 0.88 1.5 ± 4.7 0.72
MIP vs AIP 3.6 ± 8.5 0.88 3.9 ± 8.4 0.96
MidV vs AIP 2.5 ± 5.1 0.20 2.3 ± 5.2 0.58
MIP vs PCT 1.8 ± 5.6 0.80 2.3 ± 5.5 0.58
MidV vs PCT 0.9 ± 3.5 0.45 0.8 ± 3.3 0.58
MIP vs MidV 0.9 ± 3.7 0.72 1.4 ± 3.4 0.80
ΔV20 PCT vs AIP 1.6 ± 5.5 0.80 1.0 ± 5.2 0.45
MIP vs AIP 4.1 ± 7.7 0.14 4.4 ± 7.5 0.09
MidV vs AIP 2.4 ± 4.1 0.17 2.4 ± 4.6 0.24
MIP vs PCT 2.4 ± 4.4 0.17 3.4 ± 5.9 0.05
MidV vs PCT 0.8 ± 3.3 0.33 1.5 ± 4.2 0.39
MIP vs MidV 1.6 ± 3.7 0.51 1.9 ± 3.2 0.33
ΔV10 PCT vs AIP 1.3 ± 4.7 0.96 1.1 ± 4.9 0.65
MIP vs AIP 5.2 ± 5.3 0.01* 5.4 ± 5.6 0.01*
MidV vs AIP 2.4 ± 3.1 0.02* 2.5 ± 3.3 0.04*
MIP vs PCT 4.0 ± 4.5 0.03* 4.3 ± 4.3 0.03*
MidV vs PCT 1.3 ± 4.2 0.45 1.5 ± 4.2 0.33
MIP vs MidV 2.7 ± 2.8 0.03* 2.8 ± 3.1 0.04*
Relative differences for liver dose over all patients (mean ± standard deviation)
in liver SBRT between the different CT datasets for 3D-CRT and VMAT plans. PCT
planning CT, AIP average intensity projection CT, MIP maximum intensity projection
CT, MidV mid-ventilation CT. *assigns statistical significant values (p< 0.05)
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